Purple Biotech Ltd. is set to execute a 1-for-10 reverse stock split on Monday, March 2, 2024. Announced on Wednesday, February 25, this decision will adjust the number of shares held by shareholders after the market closes on Friday, February 27. The reverse split aims to enhance the company’s stock price and improve its market perception.
On Thursday, shares of Purple Biotech (NASDAQ:PPBT) opened at $0.52. The company currently has a fifty-day moving average of $0.63 and a two-hundred-day moving average of $0.86. Over the past year, the stock has experienced a low of $0.46 and a high of $3.07, reflecting significant volatility. With a market capitalization of approximately $6.70 million, the stock has a price-to-earnings (P/E) ratio of -1.63 and a beta of 0.66, indicating lower volatility compared to the market.
Analyst Ratings and Market Sentiment
Analysts have expressed cautious views regarding Purple Biotech’s stock. Weiss Ratings reiterated a “sell (e+)” rating on the shares in a report dated December 29, 2023. Additionally, Wall Street Zen downgraded the stock to a “strong sell” on November 28, 2023. Currently, according to MarketBeat, one investment analyst has assigned a “sell” rating, contributing to a consensus rating of “sell” for the company.
Despite the negative outlook from analysts, there has been some institutional interest in Purple Biotech. Notably, SmartHarvest Portfolios LLC acquired a new stake during the fourth quarter, purchasing 47,454 shares valued at approximately $31,000. As of the latest SEC filing, the institutional investor holds 0.37% of the company, while institutional investors collectively own 9.64% of the stock.
Company Overview and Pipeline
Purple Biotech is a clinical-stage company focused on developing therapies to address tumor immune evasion and drug resistance in cancer patients in the United States. Its current oncology pipeline includes several promising candidates.
The lead candidate, CM24, is a humanized monoclonal antibody designed to block the interactions of carcinoembryonic antigen-related cell adhesion molecule 1. CM24 is undergoing a Phase 2 clinical trial for treating pancreatic ductal adenocarcinoma in combination with anti-PD-1 checkpoint inhibitors.
Another pipeline asset, NT219, is a small molecule targeting insulin receptor substrate 1 and 2, as well as signal transducer and activator of transcription. This candidate is currently in Phase 1/2 clinical trials aimed at treating recurrent and/or metastatic squamous cell carcinoma of the head and neck, as well as colorectal adenocarcinoma.
Additionally, Purple Biotech is developing IM1240, a multi-valent antibody aimed at activating anti-tumoral immune responses against 5T4-positive tumors, which is still in the preclinical stage.
As the company moves forward with its reverse split and ongoing trials, investors will be closely watching its performance and developments in the competitive oncology landscape.
